October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Kristin N.: Could Elritercept Change How We Manage Anemia in Lower-Risk MDS?

Kristin N./LinkedIn

Oct 27, 2026, 03:27

Kristin N.: Could Elritercept Change How We Manage Anemia in Lower-Risk MDS?

Kristin N., Chief Executive Officer at Fast4ward Learning, shared a post on LinkedIn:

“Could elritercept change how we manage anemia in lower-risk MDS?

Elritercept (TAK-226, KER-050) is an investigational activin receptor type IIA ligand trap designed to support both early- and late-stage red blood cell maturation.

The ongoing RENEW phase 3 trial is evaluating elritercept in patients with very low-, low-, or intermediate-risk MDS with transfusion-dependent anemia, including patients with or without ring sideroblasts.

Early phase 2 data show encouraging transfusion-independence responses, while the ELRiSE phase 3 trial takes the question a step further by evaluating elritercept versus epoetin alfa in patients who have not previously received an ESA.

What makes this program particularly interesting is the potential to address anemia across a broader MDS population, rather than being limited to a specific ring sideroblast subgroup.

Elritercept remains investigational, and ongoing randomized trials will be important in defining its efficacy, safety, and potential place in treatment.”

Stay updated with Hemostasis Today.